Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, placebo-controlled study of Tiratricol in Allan-Herndon-Dudley syndrome in treated patients

Next Previous
Trial Profile

Randomized, placebo-controlled study of Tiratricol in Allan-Herndon-Dudley syndrome in treated patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tiratricol (Primary)
  • Indications Allan-Herndon-Dudley syndrome
  • Focus Therapeutic Use

Most Recent Events

  • 19 Aug 2022 According to an Egetis Therapeutics media release, in dialogue with the FDA, the company has finalized the protocol for this study, which is expected to start in the autumn of 2022.
  • 28 Jan 2022 New trial record
  • 27 Jan 2022 According to an Egetis Therapeutics media release, the company planning to conduct this study before submission for a New Drug Application in the US under the granted Fast Track Designation targeted in mid-2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top